As of 2025-07-13, the EV/EBITDA ratio of Immunitybio Inc (IBRX) is -11.80. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IBRX's latest enterprise value is 3,201.51 mil USD. IBRX's TTM EBITDA according to its financial statements is -271.33 mil USD. Dividing these 2 quantities gives us the above IBRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.1x - 13.3x | 10.7x |
| Forward P/E multiples | 20.5x - 49.7x | 35.1x |
| Fair Price | (3.31) - (0.49) | (2.34) |
| Upside | -217.7% - -117.3% | -183.4% |
| Date | EV/EBITDA |
| 2025-07-11 | -11.80 |
| 2025-07-10 | -11.99 |
| 2025-07-09 | -11.73 |
| 2025-07-08 | -11.47 |
| 2025-07-07 | -11.51 |
| 2025-07-03 | -11.51 |
| 2025-07-02 | -11.25 |
| 2025-07-01 | -11.02 |
| 2025-06-30 | -11.25 |
| 2025-06-27 | -11.44 |
| 2025-06-26 | -11.73 |
| 2025-06-25 | -11.64 |
| 2025-06-24 | -11.73 |
| 2025-06-23 | -11.64 |
| 2025-06-20 | -11.99 |
| 2025-06-18 | -11.90 |
| 2025-06-17 | -11.90 |
| 2025-06-16 | -12.84 |
| 2025-06-13 | -12.65 |
| 2025-06-12 | -13.04 |
| 2025-06-11 | -13.20 |
| 2025-06-10 | -13.52 |
| 2025-06-09 | -13.85 |
| 2025-06-06 | -12.91 |
| 2025-06-05 | -12.09 |
| 2025-06-04 | -12.19 |
| 2025-06-03 | -11.47 |
| 2025-06-02 | -11.34 |
| 2025-05-30 | -11.31 |
| 2025-05-29 | -11.12 |
| 2025-05-28 | -10.66 |
| 2025-05-27 | -10.89 |
| 2025-05-23 | -10.89 |
| 2025-05-22 | -11.38 |
| 2025-05-21 | -11.28 |
| 2025-05-20 | -12.09 |
| 2025-05-19 | -11.77 |
| 2025-05-16 | -11.90 |
| 2025-05-15 | -11.34 |
| 2025-05-14 | -10.76 |
| 2025-05-13 | -10.82 |
| 2025-05-12 | -10.34 |
| 2025-05-09 | -9.39 |
| 2025-05-08 | -9.46 |
| 2025-05-07 | -8.81 |
| 2025-05-06 | -9.20 |
| 2025-05-05 | -9.49 |
| 2025-05-02 | -10.92 |
| 2025-05-01 | -10.76 |
| 2025-04-30 | -10.82 |